HC Wainwright Cuts CalciMedica (NASDAQ:CALC) Price Target to $16.00

CalciMedica (NASDAQ:CALC) had its price objective decreased by HC Wainwright from $20.00 to $16.00 in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Oppenheimer boosted their target price on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, July 10th.

CalciMedica Stock Performance

NASDAQ:CALC opened at $3.50 on Monday. The stock’s fifty day moving average is $4.25 and its 200 day moving average is $4.63. CalciMedica has a fifty-two week low of $2.68 and a fifty-two week high of $8.38.

CalciMedica (NASDAQ:CALC) last released its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.03. As a group, equities analysts predict that CalciMedica will post -2.21 earnings per share for the current year.

Insider Transactions at CalciMedica

In related news, CEO A. Rachel Leheny acquired 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the acquisition, the chief executive officer now directly owns 130,926 shares of the company’s stock, valued at $490,972.50. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Eric W. Roberts acquired 53,333 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $3.75 per share, with a total value of $199,998.75. Following the completion of the purchase, the insider now directly owns 164,706 shares in the company, valued at $617,647.50. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO A. Rachel Leheny acquired 20,000 shares of CalciMedica stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 130,926 shares in the company, valued at $490,972.50. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 138,333 shares of company stock worth $518,119. Insiders own 41.55% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc boosted its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the period. Atria Investments Inc owned about 0.25% of CalciMedica worth $117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.